ArticleClinical and molecular hepatology2020
Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights.
Article in Clinical and molecular hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- The dynamic spectrum of steatotic liver disease: the global perspective.Nature reviews. Gastroenterology & hepatology · 2026Review
- Impact of underlying liver etiology on post-hepatectomy survival outcomes in hepatocellular carcinoma patients.Translational cancer research · 2025Article
- Multi-Cohort Exploration of Repetitive Element Transcription and DNA Methylation in Human Steatotic Liver Disease.International journal of molecular sciences · 2025Article
- Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial.Frontiers in medicine · 2025Article
- Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets.Clinical and molecular hepatology · 2024Article
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation.Nutrients · 2023Review
- Non-alcoholic fatty liver disease: the pathologist's perspective.Clinical and molecular hepatology · 2023Review
- Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease.Clinical and molecular hepatology · 2023Review
- Non-alcoholic fatty liver disease: Definition and subtypes.Clinical and molecular hepatology · 2023Review
- The effects of moderate alcohol consumption on non-alcoholic fatty liver disease.Clinical and molecular hepatology · 2023Review
- Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease.Annual review of pathology · 2023Review
- Therapeutic targets in alcohol-associated liver disease: progress and challenges.Therapeutic advances in gastroenterology · 2023Review
- Correspondence on Letter regarding "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways".Clinical and molecular hepatology · 2023Article
- Alcohol use patterns and risk of incident cataract surgery: a large scale case-control study in Japan.Scientific reports · 2022Article
- Genome-Scale Metabolic Modeling Reveals Sequential Dysregulation of Glutathione Metabolism in Livers from Patients with Alcoholic Hepatitis.Metabolites · 2022Article
- Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives.Biomedicines · 2022Review
- Natural History of Alcohol-Associated Liver Disease: Understanding the Changing Landscape of Pathophysiology and Patient Care.Gastroenterology · 2022Review
- Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease.Hepatology international · 2022Article
- MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.Clinical and molecular hepatology · 2022Review
- Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease.Diabetologia · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two major causes of steatohepatitis are alcohol and metabolic syndrome. Although the underlying causes of alcoholrelated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) differ, there are certain similarities in terms of the mode of disease progression and underlying pathophysiological mechanisms. Further, excessive alcohol consumption is often seen in patients with metabolic syndrome, and alcoholic hepatitis exacerbation by comorbidity with metabolic syndrome is an emerging clinical problem. There are certain ethnic differences in the development of both NAFLD and ALD. Especially, Asian populations tend to be more susceptible to NAFLD, and genetic polymorphisms in patatin-like phospholipase domain-containing 3 (PNPLA3) play a key role in both NAFLD and ALD. From the viewpoint of pathophysiology, cellular stress responses, including autophagy and endoplasmic reticulum (ER) stress, are involved in the development of cellular injury in steatohepatitis. Further, gutderived bacterial products and innate immune responses in the liver most likely play a profound role in the pathogenesis of both ALD and NASH. Though the recent progress in the treatment of viral hepatitis has reduced the prevalence of viral-related development of hepatocellular carcinoma (HCC), non-viral HCC is increasing. Alcohol and metabolic syndrome synergistically exacerbate progression of steatohepatitis, resulting in carcinogenesis. The gut-liver axis is a potential therapeutic and prophylactic target for steatohepatitis and subsequent carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.